1Lai CL, Liaw YF, Leung NWY, et al. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentral study in Asia of lamivudine therapy for chronic hepatitis B infection. incidence, kinetics of emergency, and correlation with disease parameters. Hepatology,1997,26:259A.
2Lan DT, K hokhar MF, Dov E, et al. Long-time therapy of chronic hepatitis B with lamivudine. Hepatology,2000,32: 828-834.
4Maria Buti,Rafael Esteban.Entecavir, FTC, L-RMAU, LdT and others[].Journal of Hepatology.2003
5Fontana RJ.Mangement of patients with decompensated HBV cirrhosis[].Seminars in Liver Disease.2003
6Hom X,Little NR,Gardner SD,et al.Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection[].Pediatric Infectious Disease.2004
7Kobayashi S,Ide T,Sata M,et al.Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers[].Journal of Hepatology.2001
8Li LL,Chun TW,Yin ML,et al.Prophylactic lamivudine prevents hepatitis B reactivation and mortality in patients receiving immunosuppression and chemotherapy[].Hepatology.2000
9Liaw YF,Sung JJY,Chow WC,et al.Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blined placebo-controlled clinical trial[].Hepatology.2003
10Liaw YF,Leung N,Guan R,et al.Asian-pacific consensus statement on the management of chronic hepatitis B:[].An updateJ Gastroenterol Hepatol.2003
5Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
